Takeda Pharmaceutical Co. will soon find out if another drug to treat type 2 diabetes will be approved for use in January.
The Food and Drug Administration has stated that the date of review for alogliptin will be January 25. It will also be reviewed to see if the alogliptin can be combined with Actos into a single tablet form.
Takeda submitted the two new drugs for approval in July 2011. Alogliptin was originally submitted for approval in 2007, but it was denied because it did not meet the requirements for the new diabetes guidelines. Reports have said that the company is very excited about the the combination drug.
Recently, reports have come forward that state that the use of the popular diabetes drug, Actos, has been linked to the increased risk of bladder cancer if it used for over a year. If this has happened to you, visit the Actos lawsuit lawyers of Williams Kherkher today by calling 800-641-9810.